Early Treatment with Imiquimod 5% Cream of Periungual Warts in Vietnam: The Poorer, the Better
DOI:
https://doi.org/10.3889/oamjms.2019.053Keywords:
Imiquimod, Periungual wartsAbstract
AIM: To evaluate the efficacy of imiquimod 5% in periungual wart treatment.
MATERIAL AND METHODS: A group of 40 patients were recruited to apply imiquimod 5 % cream once daily for 5 consecutive days per week in 8 weeks. They were classified into 3 levels: Mild (the total lesion area ≤ 25 mm2), moderate (25 mm2 <total lesion area ≤ 50 mm2), severe (total lesion area > 50 mm2). The outcome was evaluated at the 4th and the 8th week. The result was graded as excellent (complete clearance), good (≥ 50% clearance) and poor (< 50% clearance).
RESULTS: The total area of the wart lesion got decreased significantly from the beginning to the 4th and the 8th week (36.7 mm2 vs 16.8 mm2, p = 0.0001 and 16.8 mm2 vs 8.8 mm2, p = 0.01). The complete clearance rate at the 4th week was lower than that at the 8th week significantly (22.5% vs 72.5%, p = 0.04). The clearance rate of patients suffering severe warts was lower significantly than that of mild/ moderate patients (82.8% vs 45.5%, p = 0.03). The duration of the disease in people who responded completely to imiquimod was shorter than that of patients partially responded (10.2 ± 14.1 months vs 22.3 ± 14.3 months, p = 0.02). Adverse effects were not common, mild and local only. Recurrence rate after 6 months of follow up was 3.5%.
CONCLUSION: In conclusion, Imiquimod 5% cream is a safe and effective drug in the treatment of periungual warts.
Downloads
Metrics
Plum Analytics Artifact Widget Block
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Phuong Pham Thi Minh, Loan Pham Thi, Anh Tran Lan, Thuong Nguyen Van, Hung Le Van, Van Tran Cam, Marco Gandolfi, Claudio Feliciani, Francesca Satolli, Michael Michael Tirant, Aleksandra Vojvodic, Torello Lotti
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0